Evaluation of Intact Fibroblast Growth Factor 23 (FGF-23) as Predictors of Bone Integrity in Patients with Chronic Kidney Disease
Keywords:
CKD, bone disease, fibroblast growth factor- 23, FGF- 23, vitamin D, bone ALP.Abstract
Chronic kidney disease is an international public health problem affecting 5—10% of the world population. Newly discovered humoral factors- fibroblast growth factor -23 (FGF-23), that are involved in phosphate and vitamin D homeostasis. Elevated levels of the phosphate-regulating hormone fibroblast growth factor- 23 have been linked to greater risk of fractures, especially among individuals with chronic kidney disease (CKD). Therefore, this study was aimed to evaluate FGF23 as a predictor for bone loss and fractures in patients with chronic kidney disease. A case control study; involved (184) participates: 129 patients that meet inclusion criteria and 55 healthy individuals as control group. Serum intact FGF-23 level was measured using an enzyme-linked immunosorbent assay kit. Immune assay (Roche Cobas E411) and spectrophotometry (Roche Cobas C311) techniques were used to analysis other parameters. The current study showed significant differences (p< 0.05) in the BMI (26.8), uric acid (4.34), urea (28.18), creatinine (0.76), phosphorus (3.42), calcium (9.12), vitamin D (31.55), albumin (4.30), alkaline phosphatase (74.49), bone specific alkaline phosphatase (1.83), parathyroid hormone (33.51), GFR (88.15) and intact FGF- 23 (133.3) of control group in comparison with BMI (24.1), uric acid (6.53), urea (139.4), creatinine (7.69), phosphorus (6.309), calcium (8.813), vitamin D (15.14), albumin (3.79), alkaline phosphatase (120.2), bone specific alkaline phosphatase (11.85), parathyroid hormone (153.7), GFR (19.47) and intact FGF- 23 (390.1) of CKD patients; respectively. The results of this study were shown no significant differences between CKD patients and healthy control, regarding to ages (P =0.07) and gender (P =0.629). Whereas, showed significant decreases of vitamin D, albumin, calcium levels inpatients, when compared to the control group.
Downloads
References
Agoro, Rafiou, Pu Ni, Megan L. Noonan, and Kenneth E.
White. 2020. "Osteocytic FGF23 and Its Kidney
Function." Frontiers in Endocrinology 11:592.
Ammirati, Adriano Luiz. 2020. "Chronic Kidney Disease."
Revista Da Associated© Medico Brasileira 66:s03-9.
Hafez, Eman Ahmed, Sameh Abd El-mottleb Hassan,
Mohammed Abdel Monem Teama, and Fatma
Mohammed Badr. 2021. "Serum Uric Acid as a Predictor
for Nephritis in Egyptian Patients with Systemic Lupus
Erythematosus." Lupus 30(3):378-84.
Haffner, Dieter, Francesco Emma, Deborah M. Eastwood,
Martin Biosse Duplan, Justine Bacchetta, Dirk Schnabel,
Philippe Wicart, Detlef Bockenhauer, Fernando Santos,
and Elena Levtchenko. 2019. "Clinical Practice
Recommendations for the Diagnosis and Management
of X-Linked Hypophospha taemia." Nature Reviews
Nephrology 15(7):435-55.
Hameed Mohamed, Shakir, Ahmed Methab Athab, Nabeel
Khalid mohammed Ali, and Ismail Ibrahim Latif. 2019.
"Mineral Derangement and Bone Diseases in Uremic
Patients on Hemodialysis in Ibn-Sina Hemodialysis
Center/Diyala." Diyala Journal of Medicine 17(1):60-76.
Haussler, Mark R., Sarah Livingston, Zhela L. Sabir, Carol A.
Haussler, and Peter W. Jurutka. 2021. "Vitamin D
Receptor Mediates a Myriad of Biological Actions
Dependent on Its 1, 25 dihydroxyvitamin D Ligand:
Distinct Regulatory Themes Revealed by Induction of
Klotho and Fibroblast Growth Factor 23. JBMR Plus
Silva, Fernando Remiao, Luciano Saso, Katerina MaldLddovd, and Josef Maly. 2022. "Vitamin D: Sources,
Physiological Role, Biokinetics, Deficiency, Therapeutic
Use, Toxicity, and Overview of Analytical Methods for
Detection of Vitamin D and Its Metabolites." Critical
Reviews in Clinical Laboratory Sciences 59(8):517-54.
Isakova, T. et al. (2011) 'Fibroblast growth factor 23 and
risks of mortality and end-stage renal disease in
patients with chronic kidney disease', Jama, 305(23),
pp. 2432-2439.
Kameda, Tomohito, Kazuya Horikoshi, Shogo Kumagai,
Yuko Saito, and Toshiaki Yoshioka. 2020. "Adsorption of
Urea, Creatinine, and Uric Acid onto Spherical Activated
Carbon." Separation and Purification Technology
:116367.
Kawarazaki, Hiroo, Yugo Shibagaki, Seiji Fukumoto, Ryo
Kido, Katsuyuki Ando, Ichiro Nakajima, Shohei
Fuchinoue, Toshiro Fujita, Masafumi Fukagawa, and
Satoshi Teraoka. 2011. "Natural History of Mineral and
Bone Disorders After Living Donor Kidney
Transplantation: A One Year Prospective Observational
Study. Therapeutic Apheresis and Dialysis15(5):481-87.
Koppe, Laetitia, Denis Fouque, and Kamyar Kalantar
Zadeh. 2019. Kidney Cachexia or Protein energy
Wasting in Chronic Kidney Disease: Facts and
Numbers. Journal of Cachexia, Sarcopenia and Muscle
(3):479-84.
Luft, Friedrich C. 2021. "Biomarkers and Predicting Acute
Kidney Injury." Acta Physiologica 231(1):e13479.
Mace, Maria L., Klaus Olgaard, and Ewa Lewin. 2020. "New
Aspects of the Kidney in the Regulation of Fibroblast
Growth Factor 23 (Fgf23) and Mineral Homeostasis."
International Journal of Molecular Sciences 21(22):1-2O.
Nonso, C. A., C. I. Sam, B. A. Ejikeme, A. Aliyu, and D. O.
Ifeyinwa. 2019. "Responses of Urea, Creatinine and Uric
Acid to Soft Tissue and Passive Mobilization in Patients
with Renal Diseases Undergoing Haemodialysis." J
Nephrol Ther 9(326):959-2161.
Nizet, A. et al. (2020) 'Bone alkaline phosphatase: An
important biomarker in chronic kidney disease-mineral
and bone disorder', Clinica Chimica Acta, 501, pp. 198-
Staykova, Sv, Ya Bocheva, and K. Prodanova. 2018.
"Comparison of Specific Bone Biomarkers in Chronic
Kidney Disease Bulgarian Patients with Secondary
Hyperparathy roidism." IOSR J. Dental Med. Sci 17:85-
Wally, Riyadh Hussein. 2016. "Effects of Chronic Kidney
Disease on Some Liver Enzymes Activity Before and
After Dialysis." Journal of the College of Basic
Education 22(96):89-94.
Wolf, M. (2012) 'Update on fibroblast growth factor 23 in chronic kidney disease', Kidney international, 82(7), pp. 737-747.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
